Predictors determining the status of axilla in breast cancer: Where is PET/CT on that?

Huseyin Ozgur Aytac¹, Tamer Colacoglu¹, Gul Nihal Nursal², Tarik Zafer Nursal¹, Filiz Aka Bolat³, Hakan Yabanoglu¹, Sedat Yildirim¹, Gokhan Moray¹

¹Department of General Surgery, ²Department of Nuclear Medicine, ³Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey

Summary

**Purpose:** 18 F-FDG PET/CT has an acceptable specificity but a low sensitivity on the prediction of axillary lymph node (ALN) metastasis in breast cancer. We analyzed the factors that could possibly affect this prediction.

**Methods:** The records of 270 patients with T1-2 invasive breast cancer who underwent surgery, 116 of whom had been evaluated by preoperative 18 F-FDG PET/CT were reviewed. Prediction of ALN status by PET/CT according to tumor stage, estrogen receptor (ER), progesterone receptor (PgR) and HER2 status, histology, age and sentinel node properties was assessed.

**Results:** ALN metastasis was present in 62 of 131 T1 (43.7%) and 106 of 142 T2 tumors (74.6%), 20 of 46 (43.5%) ER(-) and 146 of 222 (65.8%) ER(+) tumors, 38 of 71 (53.5%) PgR(-) and 127 of 200 (63.5%) PgR(+) tumors. On multivariate analysis only the tumor size (>2 cm) independently correlated with ALN metastasis (Odds ratio/OR=3.1). None of the other parameters had statistical significance in terms of ALN prediction on FDG-PET/CT.

**Conclusion:** Though T2 tumors showed increased tendency to metastasize to the axilla, prediction of ALN metastasis in preoperative FDG-PET/CT was not associated with any of the predictive factors.

**Key words:** axillary nodes, breast cancer, CT, FDG, PET, sentinel

Introduction

One of the most reliable predictive factors for recurrence and survival in breast cancer patients is the presence of ALN metastasis [1,2]. Despite its almost 100% diagnostic accuracy, axillary lymph node dissection (ALND) has a substantial rate of arm morbidity [3]. Hence, new developments paved the way to downsize the operations for axilla in breast cancer patients. In order to determine the status of the axilla in a less invasive manner, the technique of sentinel lymph node biopsy (SLNB) was implemented [4]. Thus, it is believed that unnecessary ALND can be avoided when sentinel node (SN) is negative in patients with clinically negative axilla [5]. Recently, studies have shown that addition of ALND to any surgical procedure done for breast cancer does not affect overall survival and even local disease control [5-7]. Some authors point to the needlessness of ALND for local control even when the axilla is positive on the basis of effective radiotherapy [8,9]. Therefore, reliable information about the axillary status obtained prior to surgery may determine the decision of performing ALND and even SNLB.

Efforts for predicting the axillary status are warranted and still ongoing. For breast cancer, such a heterogeneous disease in terms of harboring cells with different biologic and molecu-
lar markers, the potential of ALN metastasis has been investigated in several studies regarding its relation with many possible predictive factors.

One of the promising imaging techniques used for staging breast cancer is Fluorine-18-labeled 2fluoro-2-deoxy-D-glucose positron emission tomography with computerized tomography (FDG-PET/CT) that provides valuable information about extra-axillary nodal status and the presence of distant metastases [10]. Although FDG-PET/CT is not an imaging technique designed for lymph node investigation, it may give considerable information about the regional nodal status when interpreted correctly. Additionally, if FDG-PET/CT can accurately and noninvasively stage the axilla, as well as the currently unevaluated internal mammary and supraclavicular nodes, it could essentially change the management of many patients with breast cancer.

There are numerous studies analyzing the relationship between axillary nodal status and FDG-PET/CT findings [11,12]. Some papers investigate the diagnostic value of FDG-PET/CT by comparing breast tumor images with prognostic criteria such as tumor size, histopathological findings and hormonal status [13]. Ekmekcioglu et al. demonstrated that high maximum standardized uptake values (SUVmax) of tumors on FDG-PET/CT images correlate with other risk factors and serve as a predictive indicator [14]. Yet, it is still questionable whether prognostic factors regarding the tumor affect the accuracy of FDG-PET/CT in predicting axillary metastases in terms of SUVmax of the axilla as no available study exists to investigate the relationship between the prognostic factors and SUVmax of the axilla. Thus, studies demonstrating the relationship between risk factors and FDG-PET/CT findings regarding the axilla are needed.

The purpose of this study was to demonstrate the role of preoperative FDG-PET/CT imaging on predicting axillary metastasis according to SUVmax of the axilla and prognostic factors influencing this prediction. Therefore, we performed a retrospective analysis to assess the acuity of FDG-PET/CT as a technique for ALN staging comparing with the pathologic findings of ALNs as the reference standard, as well as demonstrating independent predictive factors for ALN metastasis.

Methods

Data of patients who underwent surgery for invasive breast cancer within the last three years at Baskent University Adana Training and Research Hospital were examined retrospectively. This study was designed and executed after the approval of Baskent University Clinical Researches and Ethics Committee with the project number KA15/188.

Patients operated on for T1 and T2 tumors according to the Cancer Staging Manual of the American Joint Committee on Cancer [15] were enrolled in the study. Patients having had neoadjuvant hormone therapy or chemotherapy and who were currently pregnant were excluded. From May 2011 to June 2014, 270 patients with T1 (<20 mm) or T2 (>20 but ≤50 mm) tumors were operated on for breast cancer, 3 of whom had been operated on for bilateral breast cancers, creating 273 individual cases. Data were first classified into two main patient groups: those with SLNB (and ALND if necessary) and those with ALND (without SLNB) (Figure 1). Data were combined in a united group for the assessment of sentinel and non-sentinel ALN metastasis eventually. All the patient data contained pathologic breast cancer diagnosis obtained preoperatively by core biopsies.

The SLNB procedure was performed using either blue dye or both 99mTc sulfur colloid and blue dye.

All blue and/or radioactive lymph nodes were considered as SLN. Simultaneous ALND was performed when metastases were detected in SLNs.

Pathological examinations were done by a specialist team for all cases. SLNs were sliced for touch imprint and for frozen section examination and then fixed in formalin and embedded in paraffin for hematoxylin & eosin (H&E) staining and examination. Non-sentinel nodes were fixed in formalin and embedded in paraffin also for H&E examination. Immunohistochemistry using cytokeratin antibody was performed to the samples negative in the H&E examination. Metastatic lymph nodes were classified according to the size of metastatic deposit as macrometastases (tumor deposits ≥2 mm in diameter) or micrometastases (0.2-2 mm in diameter) or cell clusters or isolated tumor cells (<0.2 mm in diameter). ER and PgR staining was scored as positive or negative with a cut-off of 10% nuclear immunostaining. HER2 was evaluated according to the American Society of Clinical Oncology guidelines [16].

Statistics

Effects of clinicopathological factors like tumor size, ER, PgR and HER2 status, age and histologic subtype, SN labeling method, number of SNs excised and mean diameter of SN on predicting ALN metastasis and estimation of nodal involvement by FDG-PET/CT imaging according to SUVmax of the axilla were assessed using chi-square and Fisher exact tests in the univariate analysis. Mann-Whitney U test was used to compare data lacking normal distribution. Statistically significant predictive factors for ALN metastasis in the univariate analysis were included in a multivariate analysis using logistic regression model. The relation between age and ALN status was assessed by ROC curve
analysis and no statistical significance was observed when age was evaluated either as a continuous or a categorical variable. Therefore, patients were evaluated in two groups according to their age, whether younger or older than the median age value. The most suitable SUVmax cut-off for axillary positivity was assessed by ROC curve analysis. Also a second SUVmax cut-off, which has been commonly accepted in the literature was also subjected to logistic regression analysis [17]. All tests of significance were two-sided and a p value <0.05 was considered statistically significant. Sensitivity and specificity values with AUC for FDG-PET CT and SLNB were calculated. SPSS software (version 20.0, SPSS, Chicago, IL, USA) was used for analyses.

Results

The clinicopathological characteristics of 143 cases with clinically negative axilla treated by SLNB and consequent ALND if necessary (SLNB group) and 150 cases treated by ALND without SLNB due to clinically positive axilla (ALND group) are summarized in Table 1. Regardless of the type of axillary approach, surgical modalities selected were lumpectomy or mastectomy with or without immediate reconstruction.

Axillary metastasis (sentinel or non-sentinel) was observed in 61.5% of the cases either by SLNB, ALND or both.

The mean tumor size was 20±11 mm (range, 2-50) in the SLNB group and 20±10.5 mm (range 9-50) in the ALND group. Both SN and non-SN positivity were more frequent in patients with T2 tumors in SLNB and ALND groups and in a third group that included all the SLNB and ALND groups (united group) (Table 2).

Univariate analysis demonstrated that ER positivity was correlated with nodal positivity in the SLNB group and the united group but not in ALND group. PgR positivity was correlated with nodal positivity only in the united group but not in SLNB or ALND groups. HER2 status was not correlated with nodal positivity in either of the groups (Table 2).

The frequencies of histologic types were similar in both SNLB and ALND groups (Table 1). Actually, there were only 5 patients with pure lobular carcinomas, 2 in SLNB group and 3 in ALND group. Because of the inadequacy for statistical analysis, these 5 cases with lobular histology were analyzed within the rest 24 cases with mixed ductal and lobular histology (generating the term "carcinomas with lobular components"). The likelihood of SN positivity in the SLNB group was higher for carcinomas with lobular components and the ALN positivity in the ALND group was higher for ductal carcinomas. No difference was seen in terms of nodal positivity among histologic types in the united group (Table 2). The median age was similar in both SLNB and ALND groups (Table 1). Axillary involvement was more frequent in younger individuals (less than 50 years) in the ALND group but not in the SLNB and the united group (Table 2).

Blue dye and 99mTc sulfur colloid were used in combination for SN labeling in 15 (10%) patients.

Analysis did not show any significant differ-

---

Table 1. Patient demographics and tumor characteristics according to SLNB and ALND groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>SLNB group</th>
<th>ALND group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cases</td>
<td>143</td>
<td>150</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>49 (24-85)</td>
<td>50.6 (30-75)</td>
</tr>
<tr>
<td>Tumor stage, N (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>69 (48.3)</td>
<td>62 (47.7)</td>
</tr>
<tr>
<td>T2</td>
<td>74 (51.7)</td>
<td>68 (52.3)</td>
</tr>
<tr>
<td>Histologic type of cancer, N (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infiltrating ductal</td>
<td>126 (88.1)</td>
<td>118 (90.8)</td>
</tr>
<tr>
<td>Infiltrating lobular</td>
<td>2 (1.4)</td>
<td>3 (2.3)</td>
</tr>
<tr>
<td>Mixed infiltrating</td>
<td>15 (10.5)</td>
<td>9 (6.9)</td>
</tr>
<tr>
<td>Maximum tumor size (mm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>20 (2-50)</td>
<td>20 (9-50)</td>
</tr>
<tr>
<td>Hormone receptor status, N (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER-</td>
<td>26 (18.2)</td>
<td>20 (16)</td>
</tr>
<tr>
<td>ER+</td>
<td>117 (81.8)</td>
<td>105 (84)</td>
</tr>
<tr>
<td>PgR-</td>
<td>36 (26.3)</td>
<td>35 (28.2)</td>
</tr>
<tr>
<td>PgR+</td>
<td>101 (73.7)</td>
<td>89 (71.8)</td>
</tr>
<tr>
<td>HER2-</td>
<td>30 (22.1)</td>
<td>30 (24.4)</td>
</tr>
<tr>
<td>HER2+</td>
<td>106 (77.9)</td>
<td>95 (75.6)</td>
</tr>
</tbody>
</table>
ence in SN positivity with either labeling method (Table 2). The mean number of SNs harvested was 3 and the mean diameter was 15.5 mm; both parameters were shown not to affect ALN positivity.

SN metastasis was observed in 68 (47.5%) of 143 patients. Axillary dissection was performed in 55 of the latter 68 patients with positive SNs and in 10 of the 75 patients with negative SNs. Among these 10 patients who were subjected to axillary dissection despite negative SNs, one (1.3%) had metastatic node in her axilla, which was not detected by FDG-PET/CT. Among 31 (56.3%) patients without SN metastasis despite positive SNs (2 cases with micrometastasis), FDG-PET/CT was performed in 10 cases. FDG-PET/CT detected metastasis in 3 out of 10.

Among 24 patients with positive SNs but negative non-sentinel ALNs (one micrometastasis and 23 metastases) FDG-PET/CT was performed in 13 patients an metastasis was detected in 2 of them (Figure 1).

SNs of 13 patients were reported as negative by frozen section and corrected as positive after definite pathological studies, hence these patients were deprived of axillary dissection. Nine (69%) of the latter 13 patients with false-negative SN results were demonstrated to have micrometastasis and 4 (31%) to have macrometastasis on definite studies. The false negative ratio of frozen section was calculated as 13% for micrometastasis and 5.8% for macrometastasis with an overall ratio of 9% and negative predictive value of 85%. Among the 68 patients with positive SNs 12 (22%) had micrometastatic and 56 (88%) had macrometastatic SNs. ALN dissection was carried out in 3 of these 12 patients (false-negative result in the rest 9) with micrometastatic SNs, of which 2 (67%) had non-sentinel axillary macrometastasis. Pathologic precision of frozen examination for SNs has a sensitivity of 79% and a specificity of 100% with 90% accuracy. SLNB procedure correctly predicted non-sentinel axillary status in 40 of 55 (72.7%) patients to whom ALND was performed. The mean number of ALNs dissected was 20 and the mean number of metastatic ALNs obtained was 8.7 in the ALND group. ALN metastasis was observed in 94 of 130 (72%) patients in the ALND group, of which FDG-PET/CT determined 41 out of 46 (Figure 1).

One hundred and sixteen cases were ex-
Table 2. Relation of tumor characteristics and sentinel and non-sentinel axillary nodal status according to univariate and multivariate logistic regression analysis

<table>
<thead>
<tr>
<th>Parameter (variables in the equation)</th>
<th>Number of patients and statistical results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any axillary node (sentinel or non-sentinel) in SLNB group</td>
<td>Negative 48 Positive 21 Exp(B) 0.555 p 15</td>
</tr>
<tr>
<td>Axillary node in ALND group</td>
<td>Negative 41 Positive 21 p 0.04</td>
</tr>
<tr>
<td>Any axillary node in United group</td>
<td>Negative 49 Positive 69 p 0.01</td>
</tr>
<tr>
<td>Multivariate logistic regression parameters</td>
<td>Negative 0.319 Positive 1.376 p 0.7</td>
</tr>
<tr>
<td>SN labeling method = Blue dye + 99mTc</td>
<td>Negative 3 &lt; 0.001 Positive 54 p &lt; 0.001</td>
</tr>
<tr>
<td>SUVmax value of axillary nodes on PET/CT</td>
<td>Negative 2.431 Positive 0.491 p 0.013</td>
</tr>
<tr>
<td>Age (y)</td>
<td>Negative 0.089 Positive 0.103 p 0.845</td>
</tr>
<tr>
<td>Histologic type Infiltrating ductal carcinomas</td>
<td>Negative 0.319 Positive 1.376 p 0.7</td>
</tr>
<tr>
<td>HER2</td>
<td>Negative 0.039 Positive 0.121 p 0.567</td>
</tr>
<tr>
<td>PGR</td>
<td>Negative 0.251 Positive 0.722 p 0.047</td>
</tr>
<tr>
<td>ER</td>
<td>Negative 0.319 Positive 1.376 p 0.7</td>
</tr>
<tr>
<td>Hormone receptor status</td>
<td>Negative 0.319 Positive 1.376 p 0.7</td>
</tr>
<tr>
<td>EGFR</td>
<td>Negative 0.039 Positive 0.121 p 0.567</td>
</tr>
<tr>
<td>HER2</td>
<td>Negative 0.039 Positive 0.121 p 0.567</td>
</tr>
<tr>
<td>PGR</td>
<td>Negative 0.251 Positive 0.722 p 0.047</td>
</tr>
<tr>
<td>ER</td>
<td>Negative 0.319 Positive 1.376 p 0.7</td>
</tr>
<tr>
<td>EGFR</td>
<td>Negative 0.039 Positive 0.121 p 0.567</td>
</tr>
</tbody>
</table>
PET/CT and the axillary nodal status in breast cancer

amined with FDG-PET/CT. ROC curve analysis determined the best SUVmax cut-off of axillary nodes as 1.6, with a sensitivity of 56% and specificity of 83%. When SUVmax cut-off was estimated as 2.5, sensitivity and specificity were 42% and 90%, respectively (AUC 0.715).

Axillary nodal status according to tumor size, age, histologic subtype, diameter of largest node on FDG-PET/CT, ER, PgR and HER2 status are summarized in Table 2. Larger tumor size (p<0.001), ER positivity (p=0.005) and PgR positivity (p=0.047) were shown to be proportionally related with axillary nodal positivity, whereas age, HER2 status and histologic type were not (Table 2). Multivariate logistic regression analysis demonstrated that only large tumor size was independently correlated with presence of ALN metastasis with an OR of 3.1 (95% CI 1.1-8.3). However, none of the above mentioned parameters had statistical significance in terms of axillary nodal prediction on FDG-PET/CT with either SUVmax cut-off. Yet, logistic regression analysis also showed that, when SUVmax value of ALNs on FDG-PET/CT was above 2.5, the probability of axillary (SN or non-SN) metastasis increased significantly with an OR of 14 (95% CI 2.8-70.1) (Table 2).

Discussion

Presence of metastasis in ALNs is one of the most important determinants for prognosis of breast cancer. This makes information about the axillary status critical for treatment planning. Tumor size, hormone receptors and HER2 status and histologic type are the other known prognostic factors in breast cancer [2]. FDG-PET/CT is an imaging method often used for preoperative staging. Our aim was to demonstrate the diagnostic value of preoperative FDG-PET/CT on axillary status, considering also the effects of the accompanying prognostic factors in terms of their predictive value.

In this retrospective study, we showed that more than half of the women with early breast cancer have axillary metastasis at the time of diagnosis. We also demonstrated that breast cancer tends to metastasize to the axilla when the tumor is larger than 2 cm in diameter regardless of its histologic type, ER, PgR and HER2 status, patient age and diameter of the axillary lymph nodes. Our data also suggested that FDG-PET/CT imaging on predicting axillary metastasis has a low sensitivity (56%) but high specificity (90%) and none of the prognostic factors mentioned above affects this prediction. Tumor characteristics other than tumor size and HER2 status had different influences on ALN positivity in SNLB, ALND or united groups in univariate but not in multivariate analysis in our study. Confirming other studies, we found that the most significant predictive indicator of axillary lymph node involvement for patients with breast cancer is the tumor size [18-22]. However, we noticed that, in contrast with our results, there are some studies showing non-correlation between the primary tumor size and axillary status [23-26].

In some previous studies dealing with the relation between hormonal and SN status, ER and PgR negative status was shown to be associated with low risk of ALN metastasis [21,27]. Positive expressions of ER and PgR have been previously shown to be significantly correlated with histological grade, mitotic score and nuclear pleomorphism [28]. This can explain why ER and PgR positive tumors tend to metastasize to the axilla more frequently. In contrast, there are articles mentioning disproportion of ER and PgR status with axillary metastasis [26,29-32], while some authors demonstrated an inverse relationship, reporting that ER and PgR positive tumors metastasize less frequently to the axilla [27]. Our results also confirmed that ALN positivity was not related with ER or PgR status.

HER2 overexpressing breast cancers are known to be more aggressive with an increased locoregional recurrence rate unless treated with trastuzumab [33]. Crabb et al. specified HER2 as an independent predictor of nodal involvement in a retrospective analysis of 3,441 early-stage breast cancer cases [34]. Gulben et al. published a similar result in a study where they investigated cases according to pathologic subtypes [21]. On the contrary, confirming many of the studies in the literature, we showed that HER2 status is not a predictor of axillary metastasis [30,35,36]. To clarify this conflict it may be speculated that HER2-positive breast cancers, known to be more aggressive, perhaps tend to metastasize via the hematogenous route rather than lymphatic.

Currently, there is a bit of compromise over the effect of histologic type of breast cancer on ALN status in the literature. For instance, Aitken et al. demonstrated that lobular and mixed breast cancers are much prone to axillary metastasis [30], Tan et al. showed that ductal can-
Cancers are more likely to have positive ALNs [37]. This may be because of the fact that nodal metastases are more commonly overlooked in lobular cancers [38]. No correlation between nodal status and histologic type was noticed in our study. Nonetheless, our results comparing histologic type and axillary status may not evoke trust as lobular carcinomas were evaluated in the same group with mixed carcinomas.

Younger age was shown to be a risk factor for axillary metastasis in some previous studies [33,39]. On the contrary, in a study with 3553 cases, Purushotham et al. pointed out that older patients have much tendency to distant metastasis [40]. We demonstrated a disproportion of axillary metastasis and patient age.

No statistical difference was observed in terms of ALN positivity between SN labeling techniques in this study. This result seems to correlate with previous studies [41]. The number and size of the SN excised were also shown not to affect ALN positivity.

We demonstrated that FDG-PET/CT has low sensitivity but high specificity in predicting the ALN status, similar with other authors [42].

There are papers in the literature claiming direct correlation between the tumor size and ALN positivity on FDG-PET/CT [12,43,44]. In a study of the Ontario Oncology Group, tumor size was found to be a predictive factor, affecting the sensitivity of FDG-PET/CT in the axillary status [45]. Metabolic correlation of molecular subtypes according to hormonal status of breast cancer with tumor SUV on FDG-PET/CT has been demonstrated in several studies [46,47]. Kim et al. recently showed that subgrouping breast cancer patients according to hormone and HER types may affect the correlation of tumor SUV with ALN metastasis [48]. We couldn’t find any studies designed to assess the effect of ER, PgR and HER2 status or histology of breast cancer on the predictive value of FDG-PET/CT regarding the SUVmax of the axilla, to compare with our results. We observed that prediction of ALN status on FDG-PET/CT is not influenced by tumor size, axillary node diameter or any other predictive risk factors mentioned above.

Because of the retrospective nature of this study with a lack of completion ALND in all SLNB cases, we could not compare the efficacy of SLNB procedure and preoperative FDG-PET/CT on estimating the axillary status. Nevertheless, we can state that despite its valuable place in diagnosing nonaxillary nodes and distant metastases, as well as accompanying second malignancies, FDG-PET/CT has a low value for predicting axillary status regardless of concomitant predictive factors of breast cancer. FDG-PET/CT may help identify patients with high ALN involvement in order to canalize directly to ALND, omitting the SLNB step. However, FDG-PET/CT cannot replace SLNB or ALND due to its insufficient sensitivity. To our knowledge, this is the first study to investigate the role of almost all common predictive risk factors of breast cancer together in the diagnostic capacity of FDG-PET/CT in the prediction of axillary status according to SUVmax of axillary nodes.

Acknowledgement

We would like to thank Mrs Cagla Sariturk for her support in the assessment of the statistical analysis of our study.
References


43. Bellevre D, Blanc Fournier C, Switsers O et al. Staging the axilla in breast cancer patients with (1)8F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? Eur J Nucl Med Mol Imaging 2014;41:1105-1112.


